31,21 €
0,24 % vorgestern
L&S, 3. Oktober, 22:55 Uhr
ISIN
US88322Q1085
Symbol
TGTX
Berichte

TG Therapeutics, Inc. Aktie News

Neutral
GlobeNewsWire
11 Tage alt
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment
Neutral
GlobeNewsWire
25 Tage alt
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 24 - 26, 2025 in Barcelo...
Neutral
GlobeNewsWire
27 Tage alt
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the company's anti-CD20 monoclonal antibody, in people with relapsing forms of multiple sclerosis (RMS).
Neutral
Seeking Alpha
etwa ein Monat alt
TG Therapeutics, Inc. (NASDAQ:TGTX ) Cantor Global Healthcare Conference 2025 September 3, 2025 10:20 AM EDT Company Participants Michael Weiss - Chairman, CEO & President Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Prakhar Agrawal Senior Biotech Analyst All right. Welcome, everyone, to day 1 of Cantor's Global Healthcare Conference.
Neutral
GlobeNewsWire
etwa ein Monat alt
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S.
Neutral
GlobeNewsWire
etwa ein Monat alt
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that it has completed its previously authorized $100 million share repurchase program, which was initially announced in August 2024. Under that program, the Company repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share.
Neutral
GlobeNewsWire
etwa ein Monat alt
Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET
Neutral
The Motley Fool
2 Monate alt
TG Therapeutics Q2 Revenue Up 91%

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen